%PDF-1.4
%
71 0 obj
<>
endobj
68 0 obj
<>
endobj
130 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-02T15:47:03Z
2024-03-29T03:17:04-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T03:17:04-07:00
application/pdf
Heather
2004-412.mar
uuid:decdd6cd-1dd1-11b2-0a00-d609277d8900
uuid:decdd6cf-1dd1-11b2-0a00-d30000000000
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
160 0 obj
[164 0 R]
endobj
161 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 544.968 56.9344 Tm
(461)Tj
ET
0 0 0 0 k
53.03 70.9 203 -16.54 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 57.0904 Tm
[(W)55.1 (illiams, et al: Serum CRP)-257.3 (in SLE)]TJ
/T1_1 1 Tf
2.4835 84.9344 Td
(immunoglobulin G anti-F\(ab\))Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_1 1 Tf
6 0 0 6 171.3684 733.9253 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 176.5684 736.5654 Tm
[(and anti-DNA)-220.2 (antibody in systemic)]TJ
-12.8336 -1.25 Td
(lupus erythematosus nephritis. J Lab Clin Med 1998;132:210-22.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Galudie J, Richards C, Harnish D, Lansdorp P)110.7 (,)-0.1 ( Baumann H.)]TJ
2.175 -1.25 Td
(Interferon B2/B-cell stimulatory factor type 2 shares identity with)Tj
0 -1.25 TD
(monocyte-derived-hepatocyte-stimulating factor and regulates the)Tj
T*
[(major acute phase protein response in liver cells. Proc Nat )54.8 (Acad Sci)]TJ
0 Tc 0 Tw T*
[(USA)-220.1 (1987;84:7251-5.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Zuniga R, Markowitz GS, )54.8 (Arkachaisri )17.7 (T)74 (, Imperatore EA, D\325Agati)]TJ
2.175 -1.25 Td
(VD, Salmon JE. Identification of IgG subclasses and C-reactive)Tj
T*
(protein in lupus nephritis: the relationship between the composition)Tj
T*
[(of immune deposits and Fc gamma receptor )17.7 (T)69.9 (ype II alleles.)]TJ
T*
(Arthritis Rheum 2003;48:460-70.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Stein MP)110.7 (, Edber)17.7 (g JC, Kimberly RP)110.7 (, et al. C-reactive protein bind-)]TJ
2.175 -1.25 Td
(ing to Fc gamma RIIa on human monocytes and neutrophils is )Tj
T*
(allele-specific. J Clin Invest 2000;105:369-76.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M,)]TJ
2.175 -1.25 Td
[(Hughes GR)79.7 (V)128.9 (. Calprotectin in patients with systemic lupus )]TJ
T*
(erythematosus: relation to clinical and laboratory parameters of )Tj
0 Tc T*
[(disease activity)64.9 (. Lupus 1993;2:47-50.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875.1 (Linker)19.7 (-Israeli M, Deans RJ, )17.7 (W)79.9 (allace DJ. Elevated levels of )]TJ
2.175 -1.25 Td
(endogenous IL-6 in systemic lupus erythematosus: a putative role)Tj
T*
[(in pathogenesis. J Immunol 1991;147:1)36.8 (17-23.)]TJ
30.825 26.2661 Td
[(28.)-875.1 (Spronk PE, ter Bor)17.7 (g EJ, Limbur)17.7 (g PC, Kallenber)17.7 (g CGM. Plasma)]TJ
2.175 -1.25 Td
(concentration of IL-6 in systemic lupus erythematosus; an indicator)Tj
T*
(of disease activity? Clin Exp Immunol 1992;90:106-10.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Nakahara C, Kanemoto K, Saito N, et al. C-reactive protein )]TJ
2.175 -1.25 Td
(frequently localizes in the kidney in glomerular diseases. Clin)Tj
T*
(Nephrol 2001;55:365-70.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Jabs )17.7 (WJ, L\232gering BA, Gerke P)110.7 (, et al. )17.7 (The kidney as a second site)]TJ
2.175 -1.25 Td
(of human C-reactive protein formation in vivo. Eur J Immunol)Tj
0 Tc 0 Tw T*
(2003;33:152-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Du Clos )17.7 (TW)91.7 (, Zlock L)91.7 (T)74 (, Hicks PS, Mold C. Decreased autoantibody)]TJ
2.175 -1.25 Td
(levels and enhanced survival of \(NZB x NZW\) F1 mice treated)Tj
T*
(with C-reactive protein. Clin Immunol Immunopathol )Tj
0 Tc 0 Tw T*
(1994;70:22-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Szalai )54.8 (AJ, )17.7 (W)79.9 (eaver CT)73.9 (, McCrory MA, et al. Delayed lupus onset in)]TJ
2.175 -1.25 Td
(\(NZB x NZW\) F1 mice expressing a human C-reactive protein)Tj
T*
[(transgene. )54.8 (Arthritis Rheum 2003;48:1602-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Ridker PM, Cushman M, Stampfer MJ, )17.7 (T)35 (racy RP)110.7 (, Hennekens CH.)]TJ
2.175 -1.25 Td
(Inflammation, aspirin, and the risk of cardiovascular disease in)Tj
T*
(apparently healthy men. New Engl J Med 1997;336:973-9.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Roman MJ, Shanker B-A, Davis )54.8 (A, et al. Prevalence and correlates)]TJ
2.175 -1.25 Td
(of accelerated atherosclerosis in systemic lupus erythematosus. )Tj
0 Tc T*
(N Engl J Med 2003;349:2399-406.)Tj
ET
0 0 0 0 k
/GS0 gs
104.13 82.08 407.5 -10.83 re
f*
0.5 w
104.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
51 0 obj
<>stream
8;Z\5D6h#D#ikn#b]WP\+Mgrm40sF.7.'1j)ns/r%/q:6$%Kb*4r7_PpT\RjJQ]n^
qRiD.@h/$ooJFTMRiDp)RuQ(rnSN@9BG%Na(9)P4,*>ujWkqBdKap\n=/I.K:E%th
9?Ehs)-<'fMlsZ6UYUe8!XlLB$%?GpYEj0CojGd*C(T
\pCp0WLK'KrUf]LZ5nr'eQ1t(=1(=G?_-er6$jM@#?nh@YfQA0t
h"AB20)R
endstream
endobj
55 0 obj
[/Indexed/DeviceRGB 255 54 0 R]
endobj
54 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
76 0 obj
<>
endobj
78 0 obj
<>
endobj
32 0 obj
<>
endobj
113 0 obj
<>
endobj
135 0 obj
<>
endobj
35 0 obj
<>
endobj
33 0 obj
<>
endobj
36 0 obj
<>stream
HTPn -4]"(NcX[HC GNJ::~D&L#n~
a88hR**+,-a-Nagag1ĴpG.!@BMwi1]{k܂T[։ tż<6Zq&2˽ g=/DU.tj1KJC U` o
endstream
endobj
34 0 obj
<>stream
ALHPHJ+Symbol . H H
minuteSymbol &]!)R>}}zwovy{{xmcA\))))
endstream
endobj
77 0 obj
<>
endobj
104 0 obj
<>stream
H|TPSg&%p7VDВGj/<ȣDyQEkiUhYG;:랛tݙvg|g|8Ʒp'䁮)J0U"uƽ`:[uRk{R=4=N21FemnweKWS4 ?ż+[3v+9c=eXURMWheA1*ZQ+cddYL,LUjtUDL!K(b)
N*NJR+e "5M%r8hmblBWlù 0̒¤8`|>pTVafİ:;a#av=qJEEE/o6O;c+F>.I`$-x&T
o[jlQYVEVgN=ia`ۄ\/2`Ζ9s=M*$"d)9jЎM%yuBwߢUCt 9[;:os3xD26)Hhn26Hk!/]Y!,BvMS`3⃪xq'uu`J#+H\%ٜuĘ-%?c.AV;.C 5
n?K
%G}5]Zc=Ղp1^cx>7;@fEn7#Ҳ~P0 "CȆejL$퉊RUYVV(+TUdfx#WS
-B4b}9>urQpPdl"?
&'9Z|i`1ʾ'`-
HFUk!nӴს3w7^O&wX+:v`Qw8)>2˩k>XϘTƟ*aU vqI}]M5dKJEu-U{0/.- n=/&ZO-iC,9^Z\DO}t|0JzXO
jEӠ <(.
@ R:H lN]d}4"?d o])`P$~x